Investigating the role of TDP-43 in Alzheimer's disease
Official title: TDP-43 in Alzheimer's disease
Funded at Seattle Inst for Biomedical/clinical Res · NIH-11091529 · Data updated 2026-11-12
This study is looking at how a protein called TDP-43, which builds up in the brains of people with Alzheimer's, interacts with other proteins and affects memory and thinking, using special tests and brain scans to see how it all works.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Seattle Inst for Biomedical/clinical Res NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | September 1, 2021 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $501,206 |
| NIH project number | 5R01AG066729-05 |
| Project ID | NIH-11091529 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease who may also exhibit TDP-43 pathology.
✕Less likely to help
Patients with Alzheimer's disease who do not show TDP-43 aggregates may not benefit from this research.
What this research studies
This research focuses on understanding the role of TDP-43, a protein that aggregates in the brains of Alzheimer's disease patients, and its interaction with other proteins like tau. By using advanced models, the researchers aim to explore how TDP-43 contributes to the progression of Alzheimer's and its impact on cognitive decline. The study will involve behavioral assessments and neuroimaging to observe changes in brain function and structure. Additionally, RNA sequencing will be utilized to analyze gene expression related to these proteins.
Why it matters
Potential benefit: If successful, this research could lead to new insights into Alzheimer's disease mechanisms and potential therapeutic targets.
How similar studies have gone: Previous research has indicated that understanding the interactions of TDP-43 with other proteins in neurodegenerative diseases could lead to significant advancements in treatment strategies.
Where this research is happening
-
Seattle Inst for Biomedical/clinical Res
Seattle, United States Active
Researchers
- Principal investigator: Liachko, Nicole Faron — Seattle Inst for Biomedical/clinical Res
- Study coordinator: Liachko, Nicole Faron
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.